Showing results (481-490 of 656) with videos related to
Sort By:
Pageof 66
Cardiovascular Research|October 16, 2004
Differential effects of MCP-1 and leptin on collateral flow and arteriogenesisStephan H Schirmer, Ivo R Buschmann, Marco M Jost, et al.Medicine|September 24, 2021
Outcomes of female and male patients suffering from coronary artery disease: A nation-wide registry of patients admitted as emergencyMarkus Jäckel, Klaus Kaier, Jonathan Rilinger, et al.Journal of Molecular and Cellular Cardiology|November 16, 2020
Diabetes changes gene expression but not DNA methylation in cardiac cellsAchim Lother, Olga Bondareva, Ali R Saadatmand, et al.The American Journal of Cardiology|October 21, 2018
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial)Serge Korjian, Eugene Braunwald, Yazan Daaboul, et al.Plos One|October 3, 2012
In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in miceDominik von Elverfeldt, Constantin von zur Muhlen, Kristina Wiens, et al.Circulation|September 27, 2012
Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosisQian Zhou, Yu Mei, Takuhito Shoji, et al.Journal of the American Heart Association|October 26, 2017
Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) TrialChristina L Fanola, David A Morrow, Christopher P Cannon, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|February 27, 2007
Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongationPatrick Stoll, Nicole Bassler, Christoph E Hagemeyer, et al.Acta Cardiologica|November 14, 2023
Long-term outcomes from upgrade to cardiac resynchronisation therapy in ischaemic versus non-ischaemic heart diseaseGoekhan Yuecel, Karolina Stoesslein, Leo Gaasch, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 29, 2025
Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomyXin Chen, Christian T Wohnhaas, Denis Delić, et al.Pageof 66